Gotowa bibliografia na temat „IRINOTECAN CANCER TREATMENT”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „IRINOTECAN CANCER TREATMENT”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "IRINOTECAN CANCER TREATMENT"
Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa i in. "The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer." Journal of Clinical Oncology 37, nr 4_suppl (1.02.2019): 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.
Pełny tekst źródłaFalcone, Alfredo, Antonello Di Paolo, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Monica Lencioni, Elisabetta Pfanner, Silvia Comis, Mario Del Tacca i Pierfranco Conte. "Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients". Journal of Clinical Oncology 19, nr 15 (1.08.2001): 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.
Pełny tekst źródłaVanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber i Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview". Journal of Clinical Oncology 19, nr 5 (1.03.2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.
Pełny tekst źródłaBailly, Christian. "Irinotecan: 25 years of cancer treatment". Pharmacological Research 148 (październik 2019): 104398. http://dx.doi.org/10.1016/j.phrs.2019.104398.
Pełny tekst źródłaKockaya, Guvenc, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz i Saim Kerman. "Treatment cost of metastatic colon cancer in Turkey". Farmeconomia. Health economics and therapeutic pathways 14, nr 1 (30.01.2013): 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.
Pełny tekst źródłaRadajewska, Anna, Helena Moreira, Dorota Bęben, Oliwia Siwiela, Anna Szyjka, Katarzyna Gębczak, Paulina Nowak i in. "Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment". International Journal of Molecular Sciences 24, nr 11 (31.05.2023): 9544. http://dx.doi.org/10.3390/ijms24119544.
Pełny tekst źródłaAoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma i in. "Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer". ESMO Open 4, nr 3 (maj 2019): e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.
Pełny tekst źródłaKciuk, Mateusz, Beata Marciniak i Renata Kontek. "Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview". International Journal of Molecular Sciences 21, nr 14 (12.07.2020): 4919. http://dx.doi.org/10.3390/ijms21144919.
Pełny tekst źródłaSagawa, Tamotsu, Hironaga Satake, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato i Akihito Tsuji. "Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 155. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.155.
Pełny tekst źródłaShun, Yu-Ting, Hsien-Yung Lai, Yi-Ting Chuang i Hsuen-Fu Lin. "Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report". Clinical Medicine Insights: Case Reports 16 (styczeń 2023): 117954762211503. http://dx.doi.org/10.1177/11795476221150354.
Pełny tekst źródłaRozprawy doktorskie na temat "IRINOTECAN CANCER TREATMENT"
Schiel, Marissa Ann. "Human carboxylesterase 2 splice variants expression, activity, and role in the metabolism of irinotecan and capecitabine /". Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/1905.
Pełny tekst źródłaTitle from screen (viewed on August 28, 2009). Department of Biochemistry and Molecular Biology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): William Bosron. Includes vita. Includes bibliographical references (leaves 102-111).
Hinkle, David T. "CORRELATING IRINOTECAN AND CAPECITABINE TREATMENT FOR COLORECTAL CANCER TO GENE EXPRESSION, POLYMORPHISMS, AND CLINICAL OUTCOMES". Thesis, 2011. http://hdl.handle.net/1805/2510.
Pełny tekst źródłaColorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiation, chemotherapy, and surgery. In a Phase II clinical trial at IUSM, a multimodality approach was chosen. The patients with locally advanced rectal cancer received preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally surgery to improve response and decrease local recurrence. Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and toxicity is important for the development of more efficient and less toxic treatment strategies for patients with colorectal cancer. The goal of this study was to determine the expression levels of the genes involved in activation and metabolism of capecitabine and irinotecan in pre and post treatment specimens from these patients. The genes quantitated by real-time PCR were carboxylesterase 1 and 2 (CES1 and CES2), thymidylate synthase (TS), β-glucoronidase (β-GUS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and topoisomerase I (Topo I). The UGT1A1*28 polymorphism in UDP glucuronosyltransferase 1 is associated with SN-38 toxicity. Therefore, the UGT1A1*28 polymorphism status in patients was determined by PCR-sequencing. Correlative analysis of gene expression and UGT1A1*28 mutation with clinical outcome in this Phase II study was completed.
DAS, NIVEDITA. "IN SILICO SCREENING OF QUERCETIN ANALOGUES AS POTENTIAL INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA FOR DIARRHEA MITIGATION IN IRINOTECAN CANCER TREATMENT". Thesis, 2023. http://dspace.dtu.ac.in:8080/jspui/handle/repository/19909.
Pełny tekst źródłaChen, Ming-Cheng, i 陳明正. "Molecular Mechanism of Resistance to Irinotecan in LoVo Colon Cancer Cells, Pharmacological Mechanism of Targeted Treatment by Thymoquinone and Mechanisms of Cancer Stem Cells and miRNAs". Thesis, 2015. http://ndltd.ncl.edu.tw/handle/97204020698622003607.
Pełny tekst źródłaMesserer, Corrie Lynn. "Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer". Thesis, 2002. http://hdl.handle.net/2429/13284.
Pełny tekst źródłaKsiążki na temat "IRINOTECAN CANCER TREATMENT"
National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London: NICE, 2002.
Znajdź pełny tekst źródłaM, Lloyd Jones, i National Co-ordinating Centre for HTA (Great Britain), red. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Alton: Core Research on behalf of NCCHTA, 2001.
Znajdź pełny tekst źródłaLloyd, Jones M., National Co-ordinating Centre for HTA (Great Britain) i Health Technology Assessment Programme, red. A Rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Southampton: NCCHTA, 2001.
Znajdź pełny tekst źródłaCzęści książek na temat "IRINOTECAN CANCER TREATMENT"
Saltz, Leonard B. "Irinotecan in the Treatment of Colorectal Cancer". W Colorectal Cancer, 513–24. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_28.
Pełny tekst źródłaWagner, Lars. "Pediatric Neuroblastoma: Treatment with Oral Irinotecan and Temozolomide". W Pediatric Cancer, 209–14. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2418-1_20.
Pełny tekst źródłaFiorentini, Giammaria, Silvia Ricci Lucchi, Petros Giovanis, Maurizio Cantore, Stefano Guadagni i Giorgio Papiani. "Phase I Clinical Study of Irinotecan (CPT-11) Hepatic Arterial Infusion Chemotherapy in Hepatic Metastases from Colorectal Cancer: Preliminary Results". W Multi-Treatment Modalities of Liver Tumours, 223–28. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0547-1_18.
Pełny tekst źródłaOteyola, Ayodeji Ojo, Raffaele Pilla, Folasade Adesola Ola-Oladimeji i Omotayo Fagbuaro. "Natural Products Application and Combination Therapy in Colorectal Cancer Treatment". W Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics, 72–94. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-9258-8.ch004.
Pełny tekst źródłaStreszczenia konferencji na temat "IRINOTECAN CANCER TREATMENT"
Davidson, David, Yunzhe Wang, Raquel Aloyz i Lawrence Panasci. "Abstract 4692: ABT-888 synergizes treatment of colon cancer cell lines with irinotecan". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4692.
Pełny tekst źródłaMorano, Federica, Salvatore Corallo, Ludovic Barault, Monica Niger, Rosa Berenato, Roberto Moretto, Giovanni Fucà i in. "Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct095.
Pełny tekst źródłaWestover, David, Xiang Ling, Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio i Fengzhi Li. "Abstract 829: The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-829.
Pełny tekst źródłaGiever, Thomas A., Paul S. Ritch, James P. Thomas, Lauren A. Wiebe, George B. Haasler, Mario G. Gasparri, David Johnstone, Candice A. Johnstone, Elizabeth M. Gore i Ben George. "Abstract 813: A combination of cisplatin, irinotecan, and paclitaxel (CIP) as frontline treatment of patients with metastatic esophageal cancer (mEC)". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-813.
Pełny tekst źródłaSachdev, Jasgit C., Ramesh K. Ramanathan, Natarajan Raghunand, Jaeyeon Kim, Stephan G. Klinz, Eliel Bayever, Jonathan B. Fitzgerald i Ronald L. Korn. "Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)". W Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-01-06.
Pełny tekst źródłaKlinz, Stephan, Jinzi Zheng, Raquel De Souza, Manuela Ventura, Nancy Paz, David Hedley, David Jaffray i Jonathan Fitzgerald. "Abstract B47: Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer". W Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.panca16-b47.
Pełny tekst źródłaMoulder, S., M. Mita, C. Bradley, C. Rocha i L. Harris. "Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC)". W Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-15-01.
Pełny tekst źródłaSachdev, JC, RK Ramanathan, N. Raghunand, C. Anders, P. Munster, S. Minton, D. Northfelt i in. "Abstract OT3-02-14: A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398)". W Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-ot3-02-14.
Pełny tekst źródła